Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors.
Breast cancer cells are relatively resistant to the induction of apoptosis (AP) and drug regimens which readily activate apoptotic death, may enhance the antitumor effect. Rapid and intensive induction of apoptosis was observed in estrogen receptor positive and negative breast cancer cell cultures treated with tamoxifen (TMX) combined with the calmodulin antagonists trifluoperazine (TFP) or W7. TMX (1-5 microM) alone or calmodulin antagonists alone did not induce apoptosis. Importantly, intensive apoptosis was also induced by TMX and TFP in the cells obtained from primary human breast carcinomas. Inhibition of the Ca2+ calmodulin signaling pathway is an effective way to activate apoptotic death in epithelial cells. Combination of TMX with non-toxic calmodulin inhibitors may increase the preventive and therapeutic effects of TMX.
D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000473:pathology*; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D004357:Drug Synergism; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D002147:Calmodulin; D004965:Estrogen Antagonists; D013629:Tamoxifen; D014268:Trifluoperazine